First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC
Clinical trial NCT06238752 · COMPLETED
Trial details
- NCT number
- NCT06238752
- Sponsor
- Renmin Hospital of Wuhan University
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-01
- Primary completion
- 2023-03-01
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.